Cytel's Jim Bolognese explains a recent project with Merck that eliminated the need for a Phase 1B trial in the planned development path. Jim shows in detail the underlying methodology and Merck's own decision criteria, incorporating trial simulations in conjunction with biomarkers. As as a result, Merck saves months in development time, trial costs and speeds product revenue start (assuming regulatory approval).
The 40 minute presentation is followed by a hosted Q&A session.
Download the slides: [ Ссылка ]
Learn more about applying the technique from Cytel +1 617.661.2011
